N-(4-异丙氧基苯基)哌嗪-1-羧酰胺 | 792899-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-异丙氧基苯基)哌嗪-1-羧酰胺
• 英文名称: N-(4-isopropoxyphenyl)piperazine-1-carboxamide
• 英文别名: piperazine-1-carboxylic acid (4-isopropoxy-phenyl)-amide；N-{4-[(Propan-2-yl)oxy]phenyl}piperazine-1-carboxamide；N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
• CAS: 792899-38-8
• 化学式: C₁₄H₂₁N₃O₂
• 分子量: 263.34
• InChiKey: HLPOSBBZRPZKDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-异丙氧基苯基)哌嗪-1-羧酰胺 、 4-氯-6-甲氧基-7-(3-(哌啶-1-基)丙氧基)喹唑啉 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 坦度替尼
  参考文献：
  名称：

  改进了取代 6,7-二羟基-4-喹唑啉胺的合成：坦度替尼、厄洛替尼和吉非替尼。

  摘要：

  报道了三种取代的 6,7-二羟基-4-喹唑啉胺的合成：坦杜替尼 (1)、厄洛替尼 (2) 和吉非替尼 (3)，产量提高。中间体通过NMR表征并且通过HPLC确定纯度。

  DOI：

  10.3390/11040286
• 作为产物：
  描述：

  4-(4-Isopropoxy-phenylcarbamoyl)-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 、 氨 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 2.0h， 以97%的产率得到N-(4-异丙氧基苯基)哌嗪-1-羧酰胺
  参考文献：
  名称：

  SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS

  摘要：

  这项发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括给予一种法尼基转移酶抑制剂和一种从式I′的氨基嘧啶化合物中选择的FLT3激酶抑制剂：其中R3、B、Z、r和R1如本文所定义。本发明涵盖了用于治疗处于发展细胞增殖障碍或与FLT3有关的障碍风险（或易感）的受试者的预防和治疗方法。

  公开号：

  US20060281755A1
• 作为试剂：
  描述：

  N-(4-异丙氧基苯基)哌嗪-1-羧酰胺 、 4-氯-6-甲氧基-7-(3-(哌啶-1-基)丙氧基)喹唑啉 在 N-(4-异丙氧基苯基)哌嗪-1-羧酰胺 作用下， 以96的产率得到坦度替尼
  参考文献：
  名称：

  Molecules 2006, 11, 286-297

  摘要：

  DOI：

文献信息

• Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline
  申请人：Shih Kae-Shyang

  公开号：US20100267949A1

  公开（公告）日：2010-10-21

  A method of synthesizing 6,7-substituted 4-anilino quinazoline employs 3,4-substituted benzoic acid as an initial reactant, and the 6,7-substituted 4-anilino quinazoline is obtained by an esterifying step, a nitrating step, a reducing step, a cyclizing step, and an one-pot reaction. In the above method, the initial reactant has low cost and yield. of the 6,7-substituted 4-anilino quinazoline is high, therefore, production cost can be reduced effectively, and competitive power of the product of the 6,7-substituted 4-anilino quinazoline can be improved.

  合成6,7-取代的4-苯胺喹唑啉的方法采用3,4-取代苯甲酸作为初始反应物，通过酯化步骤、硝化步骤、还原步骤、环化步骤和一锅法反应得到6,7-取代的4-苯胺喹唑啉。在上述方法中，初始反应物成本低且产率高。6,7-取代的4-苯胺喹唑啉的产率高，因此可以有效降低生产成本，提高6,7-取代的4-苯胺喹唑啉产品的竞争力。
• LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS
  申请人：Millennium Phamaceuticals, Inc.

  公开号：US20150133460A1

  公开（公告）日：2015-05-14

  This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.

  本发明提供了一个公式(I)的化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式；制备公式(I)的化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式的合成或制造过程；以及使用该化合物，或其晶体形式，或其药物组合物，或其口服药物剂量形式，用于治疗患有或受到细胞存活、增殖和迁移相关疾病、障碍或病况的患者，包括心血管疾病（如动脉硬化和血管再狭窄）、癌症（如AML和恶性胶质瘤）、肾小球硬化、纤维化疾病和炎症。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20070021435A1

  公开（公告）日：2007-01-25

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, r and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、r和R1的定义如本文所述，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并用于预防或治疗与FLT3和/或c-kit和/或TrkB相关的细胞增殖性疾病和/或疾病。本发明还涉及包含本发明化合物的药物组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• WO2006/135719
  申请人：——

  公开号：——

  公开（公告）日：——
• NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF
  申请人：Kanter James

  公开号：US20100240893A1

  公开（公告）日：2010-09-23

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.